BioCorRx Q2 FY26 net loss narrows to $1 million; revenue drops 50.6% to $87,970 - BICX News | RalliesBioCorRx Q2 FY26 net loss narrows to $1 million; revenue drops 50.6% to $87,970
B
BICX• Quarterly results and revenue decline
- BioCorRx posted a net loss of USD 1.00 million for the quarter ended June 30, 2026, narrowing from USD 1.38 million.
- Revenue fell 50.6% to USD 87,970 versus the prior-year quarter, on lower Lucemyra distribution sales.
- Grant income more than doubled to USD 679,477, while operating expenses edged down to USD 1.55 million.
Cash position and going-concern warning
- Cash totaled USD 21,237 at June 30, 2026; net cash used in operating activities was USD 873,260 for the six months ended June 30, 2026.
- Working capital deficit stood at USD 8.23 million, with management flagging substantial doubt about going-concern over the next 12 months.
